Lansoprazole Tablet, Orally Disintegrating
Product Images NDC 68382-771

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 68382-771). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

2a6d080f 1bf7 4c77 96f9 Bfb23135fc41 01

Chemical structure of lansoprazole, showing its molecular arrangement including a benzene ring, sulfoxide group, and pyridine ring with trifluoromethoxy substitution.*

FDA Label Image

2a6d080f 1bf7 4c77 96f9 Bfb23135fc41 02

A line graph depicting the mean severity of day heartburn over days from the start of treatment. The graph compares placebo, Lansoprazole 15 mg orally disintegrating, and Lansoprazole 30 mg orally disintegrating, showing a decrease in heartburn severity with both Lansoprazole doses compared to placebo over time.*

FDA Label Image

2a6d080f 1bf7 4c77 96f9 Bfb23135fc41 03

A line graph depicting the mean severity of night heartburn over days from the start of treatment. It compares three groups: Placebo, Lansoprazole 15 mg orally disintegrating (OD), and Lansoprazole 30 mg OD. The severity decreases over time for both Lansoprazole doses more than for placebo.*

FDA Label Image

2a6d080f 1bf7 4c77 96f9 Bfb23135fc41 04

Packaging label for Lansoprazole Delayed-Release Orally Disintegrating Tablets 15 mg by Zydus Pharmaceuticals USA Inc. The label indicates a 100-tablet supply (10 x 10 unit-dose) with instructions for pharmacists and storage directions. The label includes NDC 68382-771-77 and notes the product is Rx only.*

FDA Label Image

2a6d080f 1bf7 4c77 96f9 Bfb23135fc41 05

The image shows the packaging label for Lansoprazole Delayed-Release Orally Disintegrating Tablets, 30 mg strength. The label displays the product name, strength, dosage form, and a count of 100 tablets (10 x 10 unit-dose) from Zydus Pharmaceuticals USA Inc. Instructions and pharmacy-related warnings are also visible, along with manufacturer information from Cadila Healthcare Ltd. The NDC code 68382-772-77 is featured on the label.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.